Creso Pharma has two product lines at the moment with other products and technologies in development:
- Human health products: the cannaQIX® and cannapeal range of products
- Animal health products: the anibidiol® range of products
All Creso Pharma products are produced according to the highest quality standards using Good Manufacturing Practices (GMP) quality standards. Creso Pharma’s products also conform to local regulations in their area of distribution and are standardised in dose and formulation, improving safety and efficacy.
Creso Pharma is focusing on delivery technologies that are well suited to the optimal delivery of cannabinoids - in particular of CBD full-plant extracts. These proprietary technologies, included in the anibidiol® and cannaQIX® range of products to begin with, enable Creso Pharma to release products with enhanced absorption and bioavailabilty, and in dosage forms that are attractive to patients and animals.